Swedbank AB lowered its stake in Envista Holdings Co. (NYSE:NVST – Free Report) by 93.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the company’s stock after selling 1,502,200 shares during the quarter. Swedbank AB owned approximately 0.06% of Envista worth $1,976,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Envista during the 3rd quarter valued at about $31,000. GAMMA Investing LLC boosted its position in shares of Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after acquiring an additional 726 shares during the last quarter. Huntington National Bank boosted its position in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the last quarter.
Envista Trading Up 1.5 %
NYSE NVST opened at $22.33 on Thursday. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $25.64. The firm has a market capitalization of $3.84 billion, a PE ratio of -2.87, a P/E/G ratio of 3.09 and a beta of 1.30. The stock’s 50 day moving average is $19.67 and its 200 day moving average is $18.24.
Analyst Ratings Changes
A number of brokerages have recently issued reports on NVST. Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Bank of America dropped their target price on Envista from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. downgraded Envista from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $16.00 in a research report on Thursday, August 8th. Piper Sandler boosted their target price on Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and lifted their price target for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.71.
View Our Latest Stock Analysis on NVST
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
- Five stocks we like better than Envista
- What is a Secondary Public Offering? What Investors Need to Know
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Invest in the Best Canadian StocksĀ
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Are These Companies Considered Blue Chips?
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Co. (NYSE:NVST – Free Report).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.